CSTL Castle Biosciences, Inc.
Stock · NasdaqGM · United States · Healthcare · US14843C1053
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Castle Biosciences, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
32.52 USD
-4.91%
52-week range
17.72 – 44.28
Dividend yield—
Market cap993.5M
NowoTrade score
34 Grade A
Price history
Daily prices in USD.
Updated 07 Nov 2026 09:20. Information, not advice.
Results
Next results
25 Feb 2027
in 110 days · 16:00 · estimate -0.35
Last results
-0.13 vs -0.35 estimated
05 Nov 2026 · Beat +62.4%
Beat the estimate
10 of 12
1 missed · 1 in line · 2 beats in a row
Average surprise
+101.2%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 16:00 | -0.35 | — | — | Upcoming |
| 05 Nov 2026 16:00 | -0.35 | -0.13 | +62.4% | Beat |
| 30 Jul 2026 16:00 | -0.41 | -0.07 | +82.8% | Beat |
| 06 May 2026 16:00 | -0.49 | -0.49 | -0.3% | In line |
| 26 Feb 2026 16:00 | -0.26 | -0.08 | +69.1% | Beat |
| 03 Nov 2025 16:00 | -0.51 | -0.02 | +96.1% | Beat |
| 04 Aug 2025 16:00 | -0.50 | 0.15 | +130.0% | Beat |
| 05 May 2025 16:00 | -0.07 | -0.90 | -1,269.7% | Miss |
| 27 Feb 2025 16:00 | 0.04 | 0.32 | +700.0% | Beat |
| 04 Nov 2024 16:00 | 0.01 | 0.08 | +966.7% | Beat |
| 05 Aug 2024 16:00 | -0.24 | 0.31 | +226.5% | Beat |
| 02 May 2024 16:00 | -0.31 | -0.09 | +71.2% | Beat |
| 28 Feb 2024 16:00 | -0.49 | -0.10 | +79.7% | Beat |
| 02 Nov 2023 16:00 | -0.73 | -0.26 | +64.5% | Beat |
| 02 Aug 2023 16:00 | -0.91 | -0.70 | +23.1% | Beat |
| 03 May 2023 16:00 | -0.89 | -1.10 | -24.2% | Miss |
| 28 Feb 2023 16:00 | -0.83 | -0.78 | +6.5% | Beat |
| 02 Nov 2022 16:00 | -0.97 | -0.77 | +20.4% | Beat |
| 08 Aug 2022 16:00 | -0.80 | -0.06 | +92.5% | Beat |
| 09 May 2022 16:00 | -0.74 | -0.97 | -31.8% | Miss |
| 28 Feb 2022 16:00 | -0.47 | -0.25 | +47.3% | Beat |
| 08 Nov 2021 16:00 | -0.37 | -0.47 | -26.2% | Miss |
| 09 Aug 2021 16:00 | -0.39 | -0.35 | +9.5% | Beat |
| 10 May 2021 16:00 | -0.18 | -0.17 | +8.1% | Beat |
| 08 Mar 2021 16:00 | -0.11 | -0.17 | -52.4% | Miss |
| 09 Nov 2020 16:00 | -0.15 | -0.23 | -48.4% | Miss |
| 10 Aug 2020 16:00 | -0.44 | -0.08 | +82.0% | Beat |
| 11 May 2020 16:00 | -0.05 | 0.03 | +160.0% | Beat |
| 10 Mar 2020 16:00 | -0.02 | 0.11 | +650.0% | Beat |
| 11 Nov 2019 16:00 | -0.30 | 0.02 | +107.6% | Beat |
| 03 Sep 2019 16:00 | -0.47 | -0.13 | +71.8% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 344.2M | +3.7% | -24.2M | -7.0% | -0.83 | -233.9% | 28.3M |
| 2024 | 332.1M | +51.1% | 18.2M | 5.5% | 0.62 | +129.0% | 36.5M |
| 2023 | 219.8M | +60.4% | -57.5M | -26.1% | -2.14 | +17.1% | -19.2M |
| 2022 | 137M | — | -67.1M | -49.0% | -2.58 | — | -47.3M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 06 Nov 2026 | 34.56 | 35.69 | 31.81 | 32.52 | -4.91% | 981,600 | |
| 05 Nov 2026 | 35.17 | 35.71 | 33.65 | 34.20 | -4.34% | 701,900 | |
| 04 Nov 2026 | 36.03 | 36.43 | 35.07 | 35.75 | +1.74% | 462,500 | |
| 03 Nov 2026 | 35.32 | 36.00 | 34.72 | 35.14 | +0.57% | 455,600 | |
| 02 Nov 2026 | 37.52 | 37.52 | 34.46 | 34.94 | -5.97% | 470,300 | |
| 30 Oct 2026 | 38.03 | 38.43 | 36.73 | 37.16 | -3.51% | 334,300 | |
| 29 Oct 2026 | 37.57 | 38.72 | 36.08 | 38.51 | +4.99% | 723,800 | |
| 28 Oct 2026 | 34.51 | 37.38 | 34.51 | 36.68 | +6.29% | 431,200 | |
| 27 Oct 2026 | 33.55 | 34.66 | 33.19 | 34.51 | +3.63% | 295,200 | |
| 26 Oct 2026 | 33.20 | 33.79 | 32.84 | 33.30 | +0.67% | 235,800 | |
| 23 Oct 2026 | 33.41 | 33.62 | 32.69 | 33.08 | -0.33% | 203,000 | |
| 22 Oct 2026 | 34.13 | 34.55 | 33.06 | 33.19 | -3.43% | 335,400 | |
| 21 Oct 2026 | 33.15 | 34.72 | 32.93 | 34.37 | +3.68% | 336,600 | |
| 20 Oct 2026 | 32.65 | 33.55 | 32.09 | 33.15 | +3.06% | 272,500 | |
| 19 Oct 2026 | 32.44 | 32.74 | 31.67 | 32.17 | +0.64% | 347,200 | |
| 16 Oct 2026 | 33.82 | 34.15 | 31.80 | 31.96 | -5.44% | 381,900 | |
| 15 Oct 2026 | 33.13 | 34.06 | 32.48 | 33.80 | +2.08% | 381,900 | |
| 14 Oct 2026 | 32.47 | 33.77 | 32.47 | 33.11 | +0.70% | 243,200 | |
| 13 Oct 2026 | 32.79 | 33.35 | 32.23 | 32.88 | +0.37% | 241,700 | |
| 12 Oct 2026 | 34.42 | 34.42 | 32.31 | 32.76 | -4.82% | 239,000 | |
| 09 Oct 2026 | 33.52 | 34.52 | 33.39 | 34.42 | +2.11% | 249,100 | |
| 08 Oct 2026 | 32.54 | 33.76 | 32.25 | 33.71 | +2.15% | 373,800 | |
| 07 Oct 2026 | 33.15 | 33.72 | 32.77 | 33.00 | -1.08% | 351,500 | |
| 06 Oct 2026 | 36.65 | 37.99 | 33.10 | 33.36 | -8.98% | 609,100 | |
| 05 Oct 2026 | 35.45 | 36.76 | 35.10 | 36.65 | +3.07% | 377,200 |
Page 1 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Castle Biosciences Stock Gets A Lift From Raised 2026 Outlook (opens in a new tab) Simply Wall St. · 06 Nov 2026 18:19
- Castle Biosciences Inc (CSTL) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 11:17
- Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $40 (opens in a new tab) Benzinga · 06 Nov 2026 10:14
- What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 06 Nov 2026 03:14
- Castle Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 06 Nov 2026 01:03
- Castle Biosciences (NASDAQ:CSTL) Tops Q3 Estimates and Raises 2026 Revenue Guidance on TissueCypher Momentum (opens in a new tab) ChartMill · 05 Nov 2026 23:29
- Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates (opens in a new tab) Zacks · 05 Nov 2026 21:45
- Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 05 Nov 2026 21:44
- Castle Biosciences Reports Third Quarter 2026 Results (opens in a new tab) 05 Nov 2026 21:05
- Castle Biosciences Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 05 Nov 2026 18:21
- Castle Biosciences Raises FY2026 Sales Guidance from $365.000M-$375.000M to $385.000M-$395.000M vs $373.753M Est (opens in a new tab) Benzinga · 05 Nov 2026 17:18
- New Melanoma Study Backing DecisionDx-Melanoma Could Be A Game Changer For Castle Biosciences (CSTL) (opens in a new tab) Simply Wall St. · 09 Oct 2026 06:15
- Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know (opens in a new tab) Zacks · 28 Aug 2026 17:00
- Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap? (opens in a new tab) Simply Wall St. · 27 Aug 2026 02:10
- Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect? (opens in a new tab) Zacks · 25 Aug 2026 14:55
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 34.20 USD
- Market cap
- 993.5M
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 8.3 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.1 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -497.8× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -34.78× | Weak | 14.98× |
| Price / book | 2.09× | Fair | 3.94× |
| Price / sales | 2.63× | Fair | 3.37× |
| EV / EBITDA | 101.36× | Weak | 12.96× |
| Free cash flow yield | -1.5% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 77.1% | Good | 59.2% |
| Operating margin | -2.7% | Weak | 7.4% |
| Net margin | -6.1% | Weak | 3.4% |
| Return on equity | -4.9% | Weak | 5.7% |
| Return on assets | -0.9% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 35.9% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.08× | Good | 0.46× |
| Net debt / EBITDA | -30.06× | Good | 1.5× |
| Interest cover | -497.79× | Weak | 3.26× |
| Current ratio | 5.28× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow CSTL and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.